Global Gastrointestinal Drugs 麻豆原创 Growth 2024-2030

Publication ID:

LPI03248885

Publication Date:

March 12, 2024

Pages:

112

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Gastrointestinal Drugs market size was valued at US$ 33960 million in 2023. With growing demand in downstream market, the Gastrointestinal Drugs is forecast to a readjusted size of US$ 42680 million by 2030 with a CAGR of 3.3% during review period.
The research report highlights the growth potential of the global Gastrointestinal Drugs market. Gastrointestinal Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gastrointestinal Drugs. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gastrointestinal Drugs market.
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Gastrointestinal Drugs market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Gastrointestinal Drugs market. It may include historical data, market segmentation by Type (e.g., Prescription Gastrointestinal Drug, OTC Gastrointestinal Drug), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gastrointestinal Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gastrointestinal Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gastrointestinal Drugs industry. This include advancements in Gastrointestinal Drugs technology, Gastrointestinal Drugs new entrants, Gastrointestinal Drugs new investment, and other innovations that are shaping the future of Gastrointestinal Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gastrointestinal Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Gastrointestinal Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gastrointestinal Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gastrointestinal Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gastrointestinal Drugs market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gastrointestinal Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gastrointestinal Drugs market.
麻豆原创 Segmentation:
Gastrointestinal Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug
Segmentation by application
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
Zeria (Tillotts)
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Gastrointestinal Drugs market?
What factors are driving Gastrointestinal Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gastrointestinal Drugs market opportunities vary by end market size?
How does Gastrointestinal Drugs break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Gastrointestinal Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Gastrointestinal Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Gastrointestinal Drugs by Country/Region, 2019, 2023 & 2030
2.2 Gastrointestinal Drugs Segment by Type
2.2.1 Prescription Gastrointestinal Drug
2.2.2 OTC Gastrointestinal Drug
2.3 Gastrointestinal Drugs Sales by Type
2.3.1 Global Gastrointestinal Drugs Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Gastrointestinal Drugs Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Gastrointestinal Drugs Sale Price by Type (2019-2024)
2.4 Gastrointestinal Drugs Segment by Application
2.4.1 Chronic Gastritis
2.4.2 Functional Dyspepsia
2.4.3 Peptic Ulcer
2.4.4 Acute Gastroenteritis
2.4.5 Other
2.5 Gastrointestinal Drugs Sales by Application
2.5.1 Global Gastrointestinal Drugs Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Gastrointestinal Drugs Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Gastrointestinal Drugs Sale Price by Application (2019-2024)
3 Global Gastrointestinal Drugs by Company
3.1 Global Gastrointestinal Drugs Breakdown Data by Company
3.1.1 Global Gastrointestinal Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Gastrointestinal Drugs Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Gastrointestinal Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Gastrointestinal Drugs Revenue by Company (2019-2024)
3.2.2 Global Gastrointestinal Drugs Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Gastrointestinal Drugs Sale Price by Company
3.4 Key Manufacturers Gastrointestinal Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gastrointestinal Drugs Product Location Distribution
3.4.2 Players Gastrointestinal Drugs Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Gastrointestinal Drugs by Geographic Region
4.1 World Historic Gastrointestinal Drugs 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Gastrointestinal Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Gastrointestinal Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Gastrointestinal Drugs 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Gastrointestinal Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Gastrointestinal Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Gastrointestinal Drugs Sales Growth
4.4 APAC Gastrointestinal Drugs Sales Growth
4.5 Europe Gastrointestinal Drugs Sales Growth
4.6 Middle East & Africa Gastrointestinal Drugs Sales Growth
5 Americas
5.1 Americas Gastrointestinal Drugs Sales by Country
5.1.1 Americas Gastrointestinal Drugs Sales by Country (2019-2024)
5.1.2 Americas Gastrointestinal Drugs Revenue by Country (2019-2024)
5.2 Americas Gastrointestinal Drugs Sales by Type
5.3 Americas Gastrointestinal Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gastrointestinal Drugs Sales by Region
6.1.1 APAC Gastrointestinal Drugs Sales by Region (2019-2024)
6.1.2 APAC Gastrointestinal Drugs Revenue by Region (2019-2024)
6.2 APAC Gastrointestinal Drugs Sales by Type
6.3 APAC Gastrointestinal Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Gastrointestinal Drugs by Country
7.1.1 Europe Gastrointestinal Drugs Sales by Country (2019-2024)
7.1.2 Europe Gastrointestinal Drugs Revenue by Country (2019-2024)
7.2 Europe Gastrointestinal Drugs Sales by Type
7.3 Europe Gastrointestinal Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gastrointestinal Drugs by Country
8.1.1 Middle East & Africa Gastrointestinal Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Gastrointestinal Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Gastrointestinal Drugs Sales by Type
8.3 Middle East & Africa Gastrointestinal Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gastrointestinal Drugs
10.3 Manufacturing Process Analysis of Gastrointestinal Drugs
10.4 Industry Chain Structure of Gastrointestinal Drugs
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gastrointestinal Drugs Distributors
11.3 Gastrointestinal Drugs Customer
12 World Forecast Review for Gastrointestinal Drugs by Geographic Region
12.1 Global Gastrointestinal Drugs 麻豆原创 Size Forecast by Region
12.1.1 Global Gastrointestinal Drugs Forecast by Region (2025-2030)
12.1.2 Global Gastrointestinal Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Gastrointestinal Drugs Forecast by Type
12.7 Global Gastrointestinal Drugs Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Gastrointestinal Drugs Product Portfolios and Specifications
13.1.3 AstraZeneca Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Gastrointestinal Drugs Product Portfolios and Specifications
13.2.3 Sanofi Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Bayer
13.3.1 Bayer Company Information
13.3.2 Bayer Gastrointestinal Drugs Product Portfolios and Specifications
13.3.3 Bayer Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bayer Main Business Overview
13.3.5 Bayer Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Gastrointestinal Drugs Product Portfolios and Specifications
13.4.3 Pfizer Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Information
13.5.2 GlaxoSmithKline Gastrointestinal Drugs Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 GlaxoSmithKline Main Business Overview
13.5.5 GlaxoSmithKline Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Gastrointestinal Drugs Product Portfolios and Specifications
13.6.3 Teva Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 Zeria (Tillotts)
13.7.1 Zeria (Tillotts) Company Information
13.7.2 Zeria (Tillotts) Gastrointestinal Drugs Product Portfolios and Specifications
13.7.3 Zeria (Tillotts) Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Zeria (Tillotts) Main Business Overview
13.7.5 Zeria (Tillotts) Latest Developments
13.8 Perrigo
13.8.1 Perrigo Company Information
13.8.2 Perrigo Gastrointestinal Drugs Product Portfolios and Specifications
13.8.3 Perrigo Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Perrigo Main Business Overview
13.8.5 Perrigo Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Gastrointestinal Drugs Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Purdue Pharma
13.10.1 Purdue Pharma Company Information
13.10.2 Purdue Pharma Gastrointestinal Drugs Product Portfolios and Specifications
13.10.3 Purdue Pharma Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Purdue Pharma Main Business Overview
13.10.5 Purdue Pharma Latest Developments
13.11 C.B. Fleet
13.11.1 C.B. Fleet Company Information
13.11.2 C.B. Fleet Gastrointestinal Drugs Product Portfolios and Specifications
13.11.3 C.B. Fleet Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 C.B. Fleet Main Business Overview
13.11.5 C.B. Fleet Latest Developments
13.12 Abbott
13.12.1 Abbott Company Information
13.12.2 Abbott Gastrointestinal Drugs Product Portfolios and Specifications
13.12.3 Abbott Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Abbott Main Business Overview
13.12.5 Abbott Latest Developments
13.13 Jiangzhong
13.13.1 Jiangzhong Company Information
13.13.2 Jiangzhong Gastrointestinal Drugs Product Portfolios and Specifications
13.13.3 Jiangzhong Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Jiangzhong Main Business Overview
13.13.5 Jiangzhong Latest Developments
13.14 Xian-Janssen
13.14.1 Xian-Janssen Company Information
13.14.2 Xian-Janssen Gastrointestinal Drugs Product Portfolios and Specifications
13.14.3 Xian-Janssen Gastrointestinal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Xian-Janssen Main Business Overview
13.14.5 Xian-Janssen Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.